For the hundreds of thousands of women who undergo breast augmentation each year, breast implants are often viewed as a long-term cosmetic enhancement. However, breast implants are not lifetime devices. Whether driven by local complications, the 2019 recall of Allergan BIOCELL textured implants, concerns regarding breast implant illness (BII), or a simple change in lifestyle and aesthetic preference, a growing number of patients are choosing to have their implants permanently removed.
This surgical procedure—known as an explant—has become one of the most closely watched sectors in aesthetic plastic surgery. According to American Society of Plastic Surgeons (ASPS) national procedure statistics, cosmetic breast implant removals (in augmentation patients) rose from 36,367 in 2020 to 37,679 in 2022 and 41,115 in 2023, before easing to roughly 41,300 in 2024 — a multi-year run that outpaced primary breast augmentation, which grew only about 2% over the same window. However, social media platforms and patient advocacy groups have introduced a high level of confusion regarding how the surgery should be performed. In particular, the debate over "en bloc" capsulectomy versus total capsulectomy has left many patients feeling anxious about their surgical options.
This guide provides an evidence-first breakdown of breast implant removal. We analyze the rising statistical trend of explant surgery, define the differences between implant removal and the various types of capsulectomy, synthesize the clinical consensus from the 2024 Breast Surgery Collaborative Community (BSCC), examine the evidence regarding BII symptom relief, and outline what patients should expect regarding recovery, cost, and insurance coverage.
What is the difference between explant, capsulectomy, en bloc, total, and partial capsulectomy?
To make an informed decision, patients must understand the anatomical changes that occur after breast implant placement. When an implant is inserted, the body’s immune system responds to the foreign object by forming a wall of collagen-rich scar tissue around it. This protective barrier is called the implant capsule.
An explant procedure can be performed using several surgical techniques, categorized by how the capsule is handled:
1. Simple Explantation (Implant Removal Only)
In a simple explant, the surgeon makes an incision in the capsule, slides the breast implant out, and leaves the scar-tissue capsule inside the breast. Over time, the body typically reabsorbs, softens, or thins this scar tissue, provided the capsule is healthy, thin, and free of contracture or calcification. This is the fastest, least invasive explant method with the lowest risk of surgical complications.
2. Partial Capsulectomy
A partial capsulectomy involves removing the implant along with a portion of the capsule. Surgeons often use this technique when only specific sections of the capsule are thickened, calcified, or causing contour issues, leaving the remaining healthy, thin capsule sections intact to minimize trauma to the surrounding breast tissue.
3. Total Capsulectomy
A total capsulectomy means removing the breast implant and the entire scar-tissue capsule. The surgeon dissects the capsule away from the surrounding breast tissue, the chest wall (pectoralis major muscle), and the ribs. Because the capsule is removed, this technique eliminates all scar tissue, but it is a longer, more invasive surgery that carries a higher risk of bleeding, tissue trauma, and pneumothorax (accidental puncture of the lung cavity).
4. En Bloc Capsulectomy
The term en bloc is French for "in a block" or "as a whole." In surgical oncology, an en bloc resection means removing a tumor along with a surrounding margin of healthy tissue in one single, uninterrupted piece to prevent cancer cells from spilling into the surgical site.
In breast explant surgery, a true en bloc capsulectomy means the surgeon dissects the entire capsule off the chest wall and breast tissue and removes the capsule and the implant together as one intact, unopened package. The implant is never exposed to the surgical field during the procedure.
+--------------------------------------------------------------------------+
| EXPLANATION OF TECHNIQUES |
| |
| [Simple Explant] -> Implant removed; capsule left behind. |
| [Partial Capsulectomy]-> Implant removed; hard/thick parts of capsule |
| removed. Healthy parts left. |
| [Total Capsulectomy] -> Implant removed; entire capsule dissected and |
| removed (often in pieces). |
| [En Bloc] -> Implant and capsule dissected and removed |
| together as one unopened, intact package. |
+--------------------------------------------------------------------------+
When is en bloc capsulectomy actually indicated (and what does the 2024 consensus say)?
On social media, en bloc capsulectomy is frequently promoted as the "gold standard" for all implant removals. Patients are often told that if the capsule is opened or left behind, "toxins" or silicone particles will remain in their body, preventing recovery from systemic symptoms.
However, the global scientific and surgical consensus does not support this claim.
The 2024 BSCC Consensus and Joint Society Guidelines
In 2024, the Breast Surgery Collaborative Community (BSCC)—a joint initiative endorsed by the American Society of Plastic Surgeons (ASPS), The Aesthetic Society, and the International Society of Aesthetic Plastic Surgery (ISAPS)—issued updated consensus guidance on capsulectomy terminology and indications.
The consensus, along with the ASPS/Plastic Surgery Foundation (PSF) joint position statements, outlines clear, evidence-based indications for each technique:
- En Bloc is a Cancer Operation: A complete en bloc capsulectomy is medically indicated and recommended as the standard surgical recommendation only for patients with suspected or confirmed Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) or other implant-associated malignancies. In these cases, removing the implant and capsule as an intact unit is critical to prevent the spillage of lymphoma cells into the breast pocket, which could lead to cancer recurrence.
- En Bloc is Not Indicated for Breast Implant Illness (BII): For patients experiencing systemic symptoms (such as fatigue, brain fog, joint pain, or rashes) without signs of malignancy, the consensus states that an en bloc capsulectomy is not medically necessary or indicated. Instead, a total capsulectomy or simple explantation is typically the appropriate approach, depending on the physical state of the capsule.
- The Ethics of Unnecessary En Bloc Dissection: In the peer-reviewed journal Aesthetic Surgery Journal (2024), plastic surgeon Dr. SD Bresnick published an analysis arguing that performing or promoting en bloc capsulectomy purely for self-reported BII symptoms is unethical. Because a true en bloc dissection requires aggressive dissection off the ribs and intercostal muscles, it exposes patients to significant surgical risks—including pneumothorax, severe postoperative pain, and intercostal nerve damage—without any documented clinical benefit over less invasive techniques.
- Intact Contralateral Explantation: For patients with a confirmed diagnosis of BIA-ALCL in one breast, the ASPS/PSF joint statement recommends bilateral explantation (removing both sides) with a complete en bloc capsulectomy on the affected side and at least a total capsulectomy on the unaffected side, due to the documented risk of incidental, subclinical disease in the contralateral breast.
Does removing implants and the capsule relieve breast implant illness symptoms?
Breast Implant Illness (BII) is a term used by patients and clinicians to describe a broad spectrum of systemic symptoms that develop after breast implant placement. While BII is not currently recognized as an official medical diagnosis in international disease registries, the FDA, ASPS, and The Aesthetic Society take these patient reports seriously and have funded extensive research into the phenomenon.
The primary question patients ask is: If I get an explant, will my symptoms go away?
The Clinical Evidence on Symptom Improvement
Recent peer-reviewed literature provides valuable data on patient outcomes after breast implant removal:
- The ASJ 2023 and 2024 Cohort Studies: In a major clinical study published in the Aesthetic Surgery Journal (ASJ, 2023) by Khong et al., and supported by subsequent work in 2024 by McGuire and Glicksman, researchers tracked women undergoing explant surgery for self-reported BII symptoms. The studies demonstrated that a significant majority of patients experienced substantial and sustained improvement in their systemic symptoms (such as fatigue, joint pain, muscle aches, and cognitive issues) after surgery.
- The Capsule Irrelevance Finding: Crucially, the research showed that symptom improvement occurred regardless of whether the capsule was removed. Patients who underwent simple explantation (implant only) experienced similar rates of symptom relief compared to those who underwent total or en bloc capsulectomies. This finding directly refutes the social media theory that leaving the capsule behind traps "toxins" in the body, suggesting instead that the physical removal of the implant itself (removing the primary foreign antigen) is the trigger for systemic recovery.
- Textured Implants and MAUDE Data: The FDA's Manufacturer and User Facility Device Experience (MAUDE) database — which we analyze in depth for breast implants — contains thousands of adverse event reports linking textured breast implants (particularly recalled Allergan BIOCELL models) to local complications and systemic inflammation. The removal of these specific textured models is clinically associated with a reduction in chronic inflammatory markers.
What is recovery like after breast implant removal, and how much does it cost?
Explant surgery is a major surgical procedure performed under general anesthesia, and the recovery timeline and financial costs depend on the surgical technique chosen.
Recovery Timeline
The postoperative recovery depends heavily on whether a capsulectomy was performed.
- Simple Explant Recovery: If only the implants are removed, the surgery is relatively brief (often under 45 minutes). Patients experience minimal postoperative pain and can typically return to sedentary work within 3 to 5 days.
- Capsulectomy (Total or En Bloc) Recovery: Dissecting the capsule off the chest wall is a more trauma-heavy procedure. The surgery takes 1.5 to 3 hours, and patients are often sent home with temporary surgical drains to prevent fluid accumulation (seroma) in the empty breast pocket.
- Drains: Drains are typically kept in place for 5 to 10 days until fluid output drops below a safe threshold.
- Activity Restrictions: Patients must avoid heavy lifting (greater than 10 to 15 pounds) and strenuous upper-body exercise for at least 4 weeks to allow the breast tissue to adhere back to the chest wall.
- Time Off Work: Most patients require 1 to 2 weeks off work.
Financial Costs of Explant Surgery
Because breast implant removal is often performed for non-reconstructive or cosmetic reasons, patients frequently pay out-of-pocket. Typical self-pay fees in the United States break down as follows:
- Simple Explant (Implant Only): $4,000 to $6,000.
- Explant with Total Capsulectomy: $7,500 to $12,000.
- Explant with Capsulectomy and Mastopexy (Breast Lift): $12,000 to $18,000. Because removing the volume of an implant leaves behind loose, stretched skin, many patients choose to combine their explant with a breast lift to restore a natural shape.
These ranges cover the surgeon's fee, operating room fees, and anesthesia fees. Fees scale higher in major metropolitan markets or when consulting highly specialized explant surgeons.
The Role of Capsule Pathology and Histology after Explantation
When a patient undergoes a total or partial capsulectomy, the removed capsule tissue should not simply be discarded. Standard clinical protocols and guidelines from the College of American Pathologists (CAP) recommend sending all removed capsule tissue for pathological examination (histology).
Why Pathology is Essential
- Ruling Out Malignancy: The primary reason for pathological evaluation is to rule out Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and other rare malignancies, such as breast implant-associated squamous cell carcinoma (BIA-SCC). Even if the capsule appears macroscopically normal during surgery, microscopic evaluation can detect early-stage cellular changes or atypical large cells.
- Identifying Silicone Particle Migration: In patients with older or ruptured silicone gel implants, the capsule often contains microscopic deposits of migrated silicone. Under a microscope, pathologists can identify these silicone particles within histiocytes (a type of immune cell) and document the degree of surrounding chronic inflammatory reaction, known as a foreign body giant cell reaction.
- Evaluating Calcification and Synovial Metaplasia: Chronic implant capsules often undergo calcification (hardening) or develop synovial metaplasia (where the inner lining of the capsule resembles the fluid-producing lining of a joint). Documenting these changes in the pathology report provides a clear clinical explanation for pre-operative breast firmness or pain.
What the Pathology Report Contains
A standard breast implant capsule pathology report includes:
- Gross Description: The weight, dimensions, thickness, and color of the capsule pieces, along with a description of any fluid contained within the pocket.
- Microscopic Description: The presence of fibrous tissue, chronic inflammation, histiocytes, giant cells, and any extracellular foreign material (such as silicone).
- Immunohistochemical (IHC) Staining: If atypical cells are seen, the pathologist will run specific IHC stains—most notably CD30 and ALK (Anaplastic Lymphoma Kinase). BIA-ALCL cells are characteristically CD30-positive and ALK-negative, which distinguishes them from other types of systemic lymphoma.
Patients should verify with their surgeon that capsule tissue will be sent to pathology, and they should obtain a copy of the final pathology report for their medical records. While the vast majority of pathology reviews return benign findings, this analysis is a critical safety gate in the explant process.
Does health insurance cover explant surgery, and how is it coded?
One of the most common questions patients ask is whether their health insurance policy will cover the cost of breast implant removal and capsulectomy.
The general rule is that insurance will not cover surgery performed for purely cosmetic reasons or self-reported breast implant illness. However, insurance companies do cover explantation under specific, documented medical indications.
Documented Medical Indications for Insurance Coverage
To secure insurance authorization, the surgeon must submit clinical records, imaging (ultrasound or MRI), and pathology reports proving the patient meets one of the following criteria:
- Confirmed Implant Rupture: For silicone gel-filled implants, a documented rupture (confirmed by MRI or ultrasound showing the "linguine sign" or extracapsular silicone) is covered by most major insurers (e.g., Aetna, Cigna, Blue Cross Blue Shield). Note that insurance rarely covers the replacement of a ruptured implant with a new one—only the removal.
- Severe Capsular Contracture: Most insurers cover removal if the patient has severe capsular contracture, graded as Baker Class III or Class IV.
- Baker Class III: The breast is firm, looks distorted, and is accompanied by mild discomfort.
- Baker Class IV: The breast is hard, cold to the touch, severely distorted, and painful.
- Implant-Associated Malignancy: A confirmed diagnosis of BIA-ALCL or other breast-implant-associated cancers is fully covered, including bilateral explant and bilateral complete capsulectomies.
- Chronic Infection or Extrusion: Recurrent infections that do not respond to antibiotics, or cases where the implant is extruding through the skin, are covered.
Why Insurers Require Objective Clinical Findings
In contrast to patient reports of systemic symptoms, insurance companies structure their coverage policies around objective, measurable clinical findings. This means that self-reporting symptoms of breast implant illness—such as cognitive dysfunction or fatigue—without underlying device failures is generally not accepted as a medical justification for coverage. Insurers justify this distinction by citing the lack of a standardized diagnostic test or universal diagnostic criteria for BII.
Consequently, patients seeking coverage must demonstrate objective evidence of local complications. This is why high-resolution diagnostic imaging is an indispensable step:
- Magnetic Resonance Imaging (MRI): An MRI without contrast is the gold standard for identifying silent ruptures in silicone gel breast implants. Insurers typically require the MRI report to explicitly state that the shell is compromised (showing signs like the "linguine sign" within the capsule or extracapsular gel migration) before approving implant removal.
- High-Frequency Ultrasound: For patients with saline-filled implants, a physical examination showing deflation is usually sufficient, but ultrasound can be used to document partial deflation or fluid accumulation in the surrounding pocket.
- Clinical Photography and Exam Notes: For capsular contracture, the plastic surgeon must document physical findings (such as asymmetry, immobility, and breast distortion) and grade the contracture using the Baker scale in their clinical chart.
By ensuring these objective clinical findings are thoroughly documented in your medical records, you significantly improve the probability of insurance authorization.
Coding and CPT Codes
Surgeons use specific Current Procedural Terminology (CPT) codes to bill insurance for explant procedures:
- CPT 19328: Removal of intact mammary implant.
- CPT 19330: Removal of ruptured mammary implant.
- CPT 19373: Revision of reconstructed breast (often used for capsulectomy).
- CPT 19374: Preparation of breast pocket for implant revision or capsulectomy.
If a patient meets the medical criteria, the insurer will authorize CPT 19328/19330 along with capsulectomy codes. Patients should work closely with their surgeon's billing team to compile their clinical timeline, imaging records, and physician notes before submitting a pre-authorization request.
Summary & FAQ
Permanently removing breast implants is a personal and medical decision. While social media often pushes patients toward aggressive en bloc surgeries, clinical data and global consensus statements show that less invasive options are often safer and equally effective. By understanding the data, patients can collaborate with their board-certified plastic surgeons to design a customized surgical plan based on clinical indications rather than online trends.
Do I need an en bloc capsulectomy if I have breast implant illness?
No. The 2024 BSCC consensus and peer-reviewed studies show that a complete en bloc capsulectomy is not required for BII symptom relief. En bloc is a high-risk cancer operation indicated specifically for suspected or confirmed BIA-ALCL. For BII, a total capsulectomy or simple explant is typically recommended based on the capsule's condition.
Will my symptoms improve if I have my implants removed?
Yes, clinical studies (such as Khong 2023) show that a significant majority of patients report sustained improvement in systemic BII symptoms after explant surgery, regardless of whether the capsule was removed or left behind.
How long is recovery after breast implant removal?
Simple explant recovery takes 3 to 5 days. Explant with total capsulectomy is more invasive, requiring 1 to 2 weeks off work, temporary surgical drains for 5 to 10 days, and a strict restriction on lifting or strenuous exercise for 4 weeks.
What happens to the breast skin and tissue after explant surgery?
When breast implants are permanently removed, the empty space where the implant used to sit is referred to as the "breast pocket." Initially, the breast will appear deflated, loose, or flat, as the skin and breast tissue have been stretched by the implant over time. The extent of this deflation depends on the size of the implant, the skin's elasticity, and the amount of native breast tissue present. In younger patients with good skin elasticity, the breast tissue and skin can contract naturally over a period of 6 to 12 months, resulting in a more natural, compact shape. However, in cases of severe stretch or large implants, patients often opt for a concurrent or staged mastopexy (breast lift) or fat grafting to restore volume and lift.
Sources
- U.S. Food and Drug Administration (FDA) — Risks and Complications of Breast Implants: Reference guide on implant complications, FDA labeling, and removal techniques. URL: fda.gov
- The Aesthetic Society — Patient Safety Advisory: Clinical consensus on breast implant removal and capsulectomy indications. URL: theaestheticsociety.org
- American Society of Plastic Surgeons (ASPS) / Plastic Surgery Foundation (PSF) Joint Position Statement: 2022 Joint Statement on Breast-Implant-Associated Malignancies. URL: plasticsurgery.org
- Peer-reviewed Ethics Analysis: "En Bloc Resection for Self-Reported BII Symptoms: Why Offering This Procedure Is Unethical," Bresnick SD, Aesthetic Surgery Journal, 2024. URL: academic.oup.com/asj
- Peer-reviewed Explant Trends Study: "Breast Implant Removal Surgery: A Data-driven Look at Growing Trends," Knoedler S et al., Plastic and Reconstructive Surgery Global Open, December 2024. URL: journals.lww.com/plasreconsurg-globalopen
- American Board of Cosmetic Surgery (ABCS) Explant Resource: ABCS guide on explantation with cited McGuire & Glicksman 2024 and Zhang 2023 outcomes. URL: americanboardcosmeticsurgery.org
- American Society of Plastic Surgeons (ASPS) 2024 Procedure Statistics: ASPS national database showing breast implant removals and augmentation rates. URL: plasticsurgery.org/statistics
- Clinical Outcome Study: "Symptom Improvement After Breast Implant Removal: A Prospective Cohort Study," Khong et al., Aesthetic Surgery Journal, 2023. URL: academic.oup.com/asj
